北京云嘉律师事务所 关于博爱新开源医疗科技集团股份有限公司 2023 年限制性股票激励计划 第二个归属期归属条件成就的 法律意见书 北 京 云 嘉 律师事务所 www.yunjialaw.com 北京市朝阳区光华路乙 10 号院 1 号楼众秀大厦 17 层 1701 1701-17F, Zhongxiu Building, Guanghua Road, Chaoyang District, Beijing Tel: +86 10-65501101 在新开源保证其为本次归属向本所提供的原始文件、副本材料和影印件上的 签字、签章均为真实的；其所作的陈述和说明是完整、真实和有效的；以及一切 足以影响本法律意见的事实和文件均已向本所披露，而无任何隐瞒、疏漏之处的 基础上，本所及本所经办律师遵循审慎性及重要性原则，独立、客观、公正地对 本次归属进行了查验和确认。 本所及本所经办律师依据《证券法》《律师事务所从事证券法律业务管理办 1 北京云嘉律师事务所 关于博爱新开源医疗科技集团股份有限公司 2023 年限制性股票激励计划 第二个归属期归属条件成就的 法律意见书 致：博爱新开源医疗科技集团股份有限公司 北京云嘉律师事务 ...

博爱新开源医疗科技集团股份有限公司 2024 年度独立董事述职报告（周彤） 各位股东及股东代表: 报告期内，本人作为博爱新开源医疗科技集团股份有限公司（以下简称"公 司"）独立董事，严格按照《公司法》《证券法》《深圳证券交易所上市公司 自律监管指引第 2 号——创业板上市公司规范运作》《上市公司独立董事管理 办法》等法律法规和规范性文件以及《公司章程》《独立董事制度》的相关规 定和要求，本着客观、公正、独立的原则，勤勉、尽责、忠实地履行职务，积 极出席相关会议，对公司审议决策的重大事项均要求提供相关资料进行认真审 核，必要时向公司相关部门和人员询问，并利用自身的专业知识，客观、审慎 地行使表决权，努力维护了公司整体利益和广大中小股东的合法权益，为公司 的规范运作和健康发展发挥了积极作用。现将本人 2024 年度履行独立董事职 责的基本情况报告如下： 一、独立董事基本情况 周彤，男，1967 年生，中国国籍，有美国国家居留权，医学博士。上海善 准生物科技有限公司董事长、创始人，上海疾病预防控制中心客座教授，美国 北卡中美生物科技协会理事长。1991 年毕业于上海医科大学（现复旦大学医学 院）本科，1997 年获 ...

新开源 市值管理制度 博爱新开源医疗科技集团股份有限公司 市值管理制度 二○二五年四月 1 新开源 市值管理制度 第一章 总则 第一条 为加强博爱新开源医疗科技集团股份有限公司（以下简称"公司"） 的市值管理工作，进一步规范公司的市值管理行为，维护公司及广大投资者合法 权益，根据《中华人民共和国公司法》《中华人民共和国证券法》《国务院关于 加强监管防范风险推动资本市场高质量发展的若干意见》《深圳证券交易所创业 板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上 市公司规范运作》《上市公司监管指引第 10 号——市值管理》等相关法律、行政 法规、部门规章、规范性文件及博爱新开源医疗科技集团股份有限公司章程》（以 下简称" 公司章程》"）的有关规定，结合公司实际情况，制订本制度。 第二条 本制度所称市值管理，是指公司以提高公司质量为基础，为提升公司 投资价值和股东回报能力而实施的战略管理行为。 第三条 公司应当牢固树立回报股东意识，采取措施保护投资者尤其是中小 投资者利益，诚实守信、规范运作、专注主业、稳健经营，以新质生产力的培育 和运用，推动经营水平和发展质量提升，并在此基础上做好投资者 ...

经核查公司独立董事周彤先生、赵锐女士、方拥军先生的任职经历以及相 关相关自查文件，上述人员均未在公司担任除独立董事以外的任何职务，也未 在公司主要股东担任任何职务，与公司及公司主要股东之间不存在利害关系或 其他可能妨碍其进行独立客观判断的关系，不存在影响独立性的情况，符合 《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法律法规中关于独立董事的独立性要求。 博爱新开源医疗科技集团股份有限公司 董事会 2025年4月17日 博爱新开源医疗科技集团股份有限公司董事会 关于独立董事独立性情况的评估专项意见 根据《上市公司独立董事管理办法》、《深圳证券交易所上市公司自律监 管指引第 2 号——创业板上市公司规范运作》等相关规定要求，独立董事应当 每年对独立性关于独立意见的发表情况进行自查，并将自查情况提交董事会， 董事会应当每年对在任独立董事独立性情况进行评估并出具专项意见。基于 此，博爱新开源医疗科技集团股份有限公司（以下简称"公司"）董事会就在 任独立董事独立性情况进行评估并出具如下专项意见： ...

一、独立董事基本情况 赵锐，女，1965 年出生，中国国籍，无永久境外居留权，中共党员，主任 检验师，1989 年本科毕业于北华大学医学检验系，获得医学学士学位；1989 年 8 月至 2020 年 4 月，在北京电力医院工作，曾任北京电力医院检验科主任及感 染疾控管理处处长。主持或主要负责科研立项 30 余项；发表 SCI 及核心期刊学 术论文 70 余篇；副主编及参编撰写专业书籍 8 本；曾参与制定中华人民共和国 卫生行业标准 2 项，共识 1 项。现任北京电力医院主任。 本人不在公司担任除独立董事外的其他职务，与公司及其主要股东不存在直 接或者间接利害关系，或者其他可能影响本人独立客观判断的关系，不存在影响 独立性的情况。 博爱新开源医疗科技集团股份有限公司 2024 年度独立董事述职报告（赵锐） 各位股东及股东代表: 报告期内，本人作为博爱新开源医疗科技集团股份有限公司（以下简称"公 司"）独立董事，严格按照《公司法》《证券法》《深圳证券交易所上市公司自 律监管指引第 2 号——创业板上市公司规范运作》《上市公司独立董事管理办法》 等法律法规和规范性文件以及《公司章程》《独立董事制度》的相关规定和要求 ...

新开源 舆情管理制度 博爱新开源医疗科技集团股份有限公司 舆情管理制度 新开源 舆情管理制度 第一章 总则 二○二五年四月 1 第一条 为提高博爱新开源医疗科技集团股份有限公司（以下简称"公司"） 应对各类舆情的能力，建立快速反应和应急处置机制，及时、妥善处理各类舆情 对公司股价、公司商业信誉及正常生产经营活动造成的影响，切实保护投资者合 法权益，根据相关法律、法规和规范性文件的规定及《博爱新开源医疗科技集团 股份有限公司章程》 （以下简称"《公司章程》"），结合公司实际情况，制定 本制度。 第二条 本制度所称"舆情"包括： （一）报刊、电视、网络等媒体对公司进行的负面报道； （二）社会上存在的已经或将给公司造成不良影响的传言或信息； （三）可能或者已经影响社会公众投资者投资取向，造成股价异常波动的信 息； （四）其他涉及公司信息披露且可能对公司股票及其衍生品交易价格产生 较 大影响的事件信息。 第三条 本制度适用于公司及公司全资子公司、控股子公司（以下统称"子公 司"）。 第二章 舆情管理的组织体系及其工作职责 第四条 公司应对各类舆情实行统一领导、统一组织、快速反应、协同应对。 第五条 公司成立应对舆情管 ...

博爱新开源医疗科技集团股份有限公司 2024 年度独立董事述职报告（方拥军） 各位股东及股东代表: 报告期内，本人作为博爱新开源医疗科技集团股份有限公司（以下简称"公 司"）独立董事，严格按照《公司法》《证券法》《深圳证券交易所上市公司自 律监管指引第 2 号——创业板上市公司规范运作》《上市公司独立董事管理办法》 等法律法规和规范性文件以及《公司章程》《独立董事制度》的相关规定和要求， 本着客观、公正、独立的原则，勤勉、尽责、忠实地履行职务，积极出席相关会 议，对公司审议决策的重大事项均要求提供相关资料进行认真审核，必要时向公 司相关部门和人员询问，并利用自身的专业知识，客观、审慎地行使表决权，努 力维护了公司整体利益和广大中小股东的合法权益，为公司的规范运作和健康发 展发挥了积极作用。现将本人 2024 年度履行独立董事职责的基本情况报告如下： 一、独立董事基本情况 根据《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作》《上市公司独立董事管理办法》《独立董事制度》的规定，本人就公司 2024 年度以下事项发表了意见，切实履行了独立董事的监督职责： | 序号 | 召开日 | 会议 ...

Financial Performance - The company's revenue for Q1 2025 was ¥324,863,000.55, a decrease of 17.69% compared to ¥394,687,984.97 in the same period last year[5] - Net profit attributable to shareholders was ¥80,420,300.50, down 33.75% from ¥121,387,401.37 year-on-year[5] - Basic and diluted earnings per share were both ¥0.17, reflecting a decline of 32.00% compared to ¥0.25 in the same quarter last year[5] - Operating profit fell to ¥90,839,459.16 compared to ¥143,346,308.66 in the previous period, a decrease of about 36.6%[24] - Net profit for the period was ¥79,771,301.77, down from ¥120,924,966.70, reflecting a decline of approximately 34.1%[24] - Total operating revenue decreased to ¥324,863,000.55 from ¥394,687,984.97, representing a decline of approximately 17.6% year-over-year[23] Cash Flow - The net cash flow from operating activities decreased by 63.26% to ¥47,514,176.29 from ¥129,324,196.47 in the previous year[5] - Operating cash inflow decreased slightly by 2.10% to ¥351,655,897.01 from ¥359,217,162.55 in the previous year[10] - Cash inflow from financing activities increased by 27,140.00% to 245,160,000.00, mainly due to an increase in cash received from borrowings[11] - Cash inflow from investment activities was $290,000,000.00, significantly higher than $913,188.00 in the previous period[26] - Net cash flow from investment activities was $200,806,519.83, a turnaround from a negative $138,217,291.74 in the previous period[26] - Cash received from operating activities was $351,655,897.01, slightly down from $359,217,162.55 in the previous period[26] - Total cash outflow from operating activities was $304,141,720.72, an increase from $229,892,966.08 in the previous period[26] - Cash received from tax refunds was $19,134,427.09, a significant increase from $1,124,453.20 in the previous period[26] Assets and Liabilities - Total assets increased by 2.86% to ¥4,497,035,940.74 from ¥4,372,054,795.55 at the end of the previous year[5] - Total current assets increased to 1,833,434,146.75 from 1,511,752,553.06, reflecting a significant growth in liquidity[19] - Cash and cash equivalents rose to 841,890,471.25 from 547,327,751.31, indicating improved cash position[19] - Total liabilities increased to ¥811,022,838.61 from ¥764,369,013.92, reflecting a growth of about 6.1%[21] - The company's equity attributable to shareholders increased to ¥3,716,911,036.74 from ¥3,637,934,717.51, a rise of approximately 2.2%[21] Shareholder Information - The total number of common shareholders at the end of the reporting period was 22,718, with no preferred shareholders having restored voting rights[13] - The largest shareholder, Wang Donghu, holds 8.68% of shares, amounting to 42,095,222 shares, with 27,350,000 shares pledged[13] - The total number of restricted shares at the end of the period remained at 36,226,876, indicating stable management of shareholding[16] - The company has no preferred shareholders and no changes in restricted shares during the reporting period[15] Research and Development - Research and development expenses rose by 57.65% to ¥21,533,233.95 from ¥13,658,788.28 in the same quarter last year[10] - Research and development expenses increased to ¥21,533,233.95 from ¥13,658,788.28, marking a rise of about 57.5% year-over-year[24] Borrowings and Financing - The company reported a significant increase in long-term borrowings by 181.91%, reaching ¥58,114,509.38 compared to ¥20,614,509.38 at the end of the previous year[10] - The company reported a significant increase in cash outflow from financing activities, which rose by 1,675.58% to 206,497,499.56[11] Future Outlook - The company plans to focus on expanding its market presence and investing in new technologies to drive future growth[23]

Financial Performance - The company reported a revenue of 300 million CNY for the last quarter, representing a 15% increase year-over-year[14]. - The company's operating revenue for 2024 was CNY 1,606,320,028.31, representing a 1.45% increase compared to CNY 1,583,417,842.97 in 2023[19]. - Net profit attributable to shareholders decreased by 29.07% to CNY 349,680,187.51 in 2024 from CNY 493,027,339.92 in 2023[19]. - Cash flow from operating activities decreased by 47.56% to CNY 256,030,360.20 in 2024 from CNY 488,252,026.37 in 2023[19]. - Basic earnings per share fell by 30.48% to CNY 0.73 in 2024 from CNY 1.05 in 2023[19]. - The company reported a significant decline in quarterly net profit, with Q4 2024 net profit at CNY 38,437,017.65, down from CNY 121,387,401.37 in Q1 2024[21]. - The overall business performance remains strong, with no significant changes in the main business and products during the reporting period[43]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of 2.5 RMB per 10 shares to all shareholders, based on a total of 484,700,005 shares[4]. Market Expansion and Growth Strategies - The company expects a revenue guidance of 350 million CNY for the next quarter, which would be a 16.67% increase from the current quarter[14]. - Market expansion plans include entering two new provinces, projected to increase market share by 5%[14]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 100 million CNY allocated for this purpose[14]. - A new strategic partnership has been established with a leading healthcare provider to improve service delivery and patient outcomes[14]. - The company aims to enhance its digital marketing efforts, with a planned increase in budget by 25% to boost online engagement[14]. - Future projections suggest continued growth in revenue, with expectations of maintaining or increasing current performance levels[52]. - The company is exploring new product development and technological advancements to enhance its market position[52]. - The company has outlined plans for market expansion, particularly in the healthcare sector, to capitalize on emerging opportunities[52]. Research and Development - The company is investing 10 million CNY in R&D for new technologies aimed at enhancing diagnostic capabilities[14]. - The company has established a strong R&D capability, focusing on technological and product innovation, and is one of the earliest enterprises in China to industrialize PVP series products[46]. - The company has invested in several R&D companies, including Guangzhou Weirong Medical Technology Co., Ltd., to enhance its capabilities in precision diagnostics and treatment[37]. - The company is focusing on expanding its market reach through the development of new dental technologies and products, aiming to enhance user experience and satisfaction[29][30][32][33][34][36][37][38][39][40]. - The company is actively pursuing technology research and product development projects to innovate within the healthcare sector[62]. - The company has a strong focus on research and development, particularly in the field of pharmaceutical excipients, to enhance its product offerings and market competitiveness[81]. Product Development and Innovation - New product launches are anticipated to contribute an additional 50 million CNY in revenue over the next fiscal year[14]. - The company has developed a fully autonomous CAR-T cell production base, which is the only one in China with complete intellectual property rights[36]. - The company has introduced a new line of dental care products, projected to generate an additional $5 million in revenue within the first year[60]. - The company has developed a new acrylic-maleic acid copolymer sodium salt product with independent intellectual property rights, which contains high-density carboxyl groups and can be used as a chelating agent and dispersant for water scale prevention[118]. - The introduction of intelligent classification algorithms aims to improve the efficiency and accuracy of cervical cancer screening[119]. - The company has developed a reagent kit for single-cell nuclear suspension preparation, increasing product sales revenue and expanding service range[121]. Risk Management and Compliance - The company has detailed potential risks and countermeasures in the "Management Discussion and Analysis" section of the report[4]. - The report emphasizes the commitment of the board and management to ensure the accuracy and completeness of the financial report[4]. - The company has established a quality management system compliant with ISO 9001:2015 standards, applicable to the production of pharmaceutical excipients, ensuring product quality and regulatory compliance[78]. - The company has received a certification for its occupational health and safety management system, compliant with ISO 45001:2018, enhancing workplace safety standards[79]. Asset Management and Investments - Total assets increased by 8.77% to CNY 4,372,054,795.55 at the end of 2024 from CNY 4,019,691,116.69 at the end of 2023[19]. - The company has established a strong brand reputation in the chemical sector, making it difficult for new entrants to replicate its success quickly[49]. - The company has secured land use rights through various certificates, ensuring legal compliance and operational legitimacy[51]. - The company has multiple industrial land use rights with expiration dates ranging from 2051 to 2060, indicating long-term operational stability[51]. User Engagement and Customer Base - User data indicates a growth in active users by 20% compared to the previous quarter, reaching 1.2 million active users[14]. - The user base expanded to 1.5 million active users, representing a 20% increase compared to the previous quarter[56]. - The company reported a significant increase in user data, with a growth rate of 25% year-over-year in the last quarter[57]. Sustainability and Corporate Responsibility - The company is focusing on sustainability initiatives, with a goal to reduce carbon emissions by 25% over the next five years[57]. - The company has initiated a sustainability program aimed at reducing operational costs by 15% over the next three years[62]. - The company has completed a third-party audit of greenhouse gas emissions[99]. Regulatory Approvals and Certifications - The company has obtained various international certifications for its products, including the European Pharmacopoeia suitability certificates for Povidone K30, K25, and K90, valid until April 13, 2027, June 9, 2028, and June 23, 2028 respectively[81]. - Heer Medical received multiple product approvals, including a cell preservation solution and a fully automated DNA quantification system, with effective dates extending to 2025 and 2026[82][83]. - The company has received high-tech enterprise certification in multiple provinces, including Henan and Hunan, with certificates valid for three years, enhancing its market credibility and potential for tax benefits[77].

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Xin Kai Yuan, a company in the chemical products and precision medical industry, with a current stock price of 14.92 yuan and a market capitalization of 7.232 billion yuan [1][2] - Xin Kai Yuan's rolling price-to-earnings (PE) ratio stands at 18.11, significantly lower than the industry average PE of 50.88 and the median PE of 35.81, indicating a relatively undervalued position within its sector [1][2] - As of March 31, 2025, Xin Kai Yuan has 22,700 shareholders, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder, reflecting a decrease of 1,100 shareholders since the last report [1] Group 2 - The latest financial results for Xin Kai Yuan show a revenue of 1.111 billion yuan for the third quarter of 2024, representing a year-on-year decline of 7.92%, while net profit decreased by 23.13% to 311 million yuan, with a gross profit margin of 52.10% [1] - The company's main business segments include fine chemicals and precision medicine, with key products such as PVPK30, PVP-I, and various diagnostic services, indicating a diverse product portfolio [1]